# ClaraVision – 12‑Month Milestone Roadmap  
**Founder:** Maya Chen  
**Company:** ClaraVision  
**Domain:** Medical Imaging (Anomaly Detection for MRI & CT)  
**Deployment Target:** On‑premise hospital networks (HIPAA‑compliant)  
**12‑Month Success Vision (Month 12):**  
> ClaraVision’s anomaly‑detection model is running in production across **three** hospital networks, continuously improving via **NVIDIA FLARE‑powered federated learning**, delivering a measurable reduction in radiologist false‑negative rates and establishing the proprietary data flywheel that underpins the Series A narrative.

---

## QUARTERLY MILESTONES  

| Quarter | Technical Milestone (Stack‑Specific) | NVIDIA Tool to Activate | Success Metric (Quantitative) |
|---------|--------------------------------------|--------------------------|------------------------------|
| **Q1 – Foundation**<br>*(Months 1‑3)* | • Harden the MONAI‑based preprocessing pipeline to ingest DICOM studies directly from on‑premise PACS via TLS‑encrypted DICOM‑C‑STORE.<br>• Containerize the PyTorch anomaly‑detection model with **NVIDIA Triton Inference Server (NIM)** for GPU‑accelerated inference on a single‑node DGX‑A100 testbed.<br>• Institute a vision‑alignment workshop (founder → CTO → lead ML engineer) to lock the model architecture, loss function, and performance thresholds. | **NVIDIA NIM** (Triton Inference Server) + **MONAI** (already in stack) | • **Data ingest latency ≤ 200 ms** per study.<br>• **Model inference latency ≤ 150 ms** on GPU (batch = 1).<br>• **Vision‑alignment sign‑off** documented; all engineering tickets reflect the founder‑defined spec. |
| **Q2 – Validation**<br>*(Months 4‑6)* | • Run a **retrospective validation study** on de‑identified MRI/CT datasets from two partner hospitals (≥ 5 k scans each) using the MONAI‑NIM pipeline.<br>• Implement **MONAI Label** for active learning‑driven annotation of uncertain cases to improve label efficiency.<br>• Produce a **HIPAA‑compliant audit log** for all data accesses and model versioning (using MLflow with encrypted backend). | **MONAI Label** (active learning) + **NVIDIA AI Enterprise** (for secured MLflow & monitoring) | • **AUC ≥ 0.92** on held‑out test set (target disease‑specific anomaly).<br>• **Annotation efficiency gain ≥ 30 %** vs. manual labeling.<br>• **Audit log completeness ≥ 99 %** (no gaps). |
| **Q3 – Scale**<br>*(Months 7‑9)* | • Deploy **NVIDIA FLARE** to enable **cross‑hospital federated learning** (FL) between the two validation hospitals and a third site (newly onboarded).<br>• Federated averaging scheme: local epochs = 5, aggregation round = 2 weeks, secure aggregation via TLS + differential privacy (ε = 1.0).<br>• Integrate FL metrics into the existing MONAI‑NIM monitoring dashboard (Prometheus + Grafana). | **NVIDIA FLARE** (FL framework) + **NVIDIA Triton** (for inference at each node) | • **Global model AUC improvement ≥ 0.03** over the best local model after 4 FL rounds.<br>• **FL convergence** (loss variance < 0.01) achieved by round 4.<br>• **Zero PHI leakage** verified via third‑party privacy audit. |
| **Q4 – Production**<br>*(Months 10‑12)* | • Harden the FL‑enabled inference service for **on‑premise deployment**: install Triton‑based NIM servers inside each hospital’s secure VLAN, orchestrated with **NVIDIA Fleet Command** for zero‑touch updates.<br>• Implement **model drift detection** (statistical test on inference embeddings) with automatic retraining trigger.<br>• Generate **real‑world performance report** (sensitivity, specificity, radiologist time‑saved) for each site. | **NVIDIA Fleet Command** (orchestration) + **NVIDIA Triton** (NIM) + **MONAI** (post‑processing) | • **Production uptime ≥ 99.5 %** per site.<br>• **Model drift detection latency ≤ 24 h**; retraining completed within 48 h of trigger.<br>• **Radiologist workflow impact:** ≥ 15 % reduction in average read time per study, validated via time‑motion study. |

---

## BENEFIT ACTIVATION SCHEDULE  

| Inception Benefit | Activation Timing | Details / Usage |
|-------------------|-------------------|-----------------|
| **GPU Cloud Credits (GCP)** | Q1‑Q4 (staggered) | • **Q1:** $5,000 – set up GCP project, enable Confidential VMs for HIPAA‑safe data ingestion tests.<br>• **Q2:** $10,000 – run large‑scale MONAI Label active‑learning experiments and baseline model training.<br>• **Q3:** $15,000 – scale FLARE federated training across three simulated hospital tenants (using GCP Confidential VMs + GPUs).<br>• **Q4:** $20,000 – production‑scale inference benchmarking, load‑testing, and final model packaging for on‑prem delivery. |
| **NVIDIA AI Enterprise License** | Q2 (post‑validation) | Provides secured containers for Triton, MONAI, and MLflow with enterprise support; enables HIPAA‑BAA‑ready deployment. |
| **NVIDIA DLI Training** | Q1 (foundation) & Q3 (scale) | • **Q1:** *Fundamentals of Deep Learning for Medical Imaging* (2‑day workshop) – aligns team on MONAI best practices.<br>• **Q3:** *Federated Learning with NVIDIA FLARE* (hands‑on lab) – prepares engineers for secure cross‑site training. |
| **Technical Go‑to‑Market Support** | Q4 | Access to NVIDIA healthcare solutions architect for co‑creating hospital‑level deployment playbooks and reference architecture. |
| **Preferred Pricing on NVIDIA Hardware** | Q4 (if hardware purchase considered) | Eligibility for discounted DGX/A100 nodes for future on‑premise edge servers. |
| **Co‑Marketing & Investor Relations** | Q3‑Q4 | Joint press release on federated learning milestone; inclusion in NVIDIA Inception healthcare showcase; investor‑ready demo video production support. |

### GCP Credit Allocation Summary  

| Quarter | Credits (USD) | Primary Use |
|---------|---------------|-------------|
| Q1 | $5,000 | Environment setup, secure ingest tests, baseline model containerization |
| Q2 | $10,000 | Large‑scale annotation & model training, active‑learning loops |
| Q3 | $15,000 | Federated learning simulations, secure aggregation experiments |
| Q4 | $20,000 | Production inference benchmarking, load testing, final model packaging |

**Total GCP credits activated:** **$50,000** (typical Inception seed‑stage allocation).

---

## INVESTOR MILESTONE MARKERS  

| Milestone (Quarter) | Why It’s an Investor Proof Point | Recommended Fundraising Timing |
|---------------------|----------------------------------|--------------------------------|
| **Q2 – Validation (AUC ≥ 0.92, annotation efficiency gain ≥ 30 %)** | Demonstrates **technical viability** and **clinical relevance** on real hospital data; de‑risks the core AI claim. | Begin **Series A conversations** immediately after Q2 close (Month 6) – use validation deck to show product‑market fit with early‑stage hospital partners. |
| **Q3 – Scale (Federated learning AUC uplift ≥ 0.03, zero PHI leakage)** | Shows **proprietary data flywheel** is operational: each new hospital improves the model without exposing data, directly supporting the investor narrative of a defensible moat. | **Follow‑up** after Q3 (Month 9) – present FL results as traction metric; ideal for **bridge round** or to strengthen Series A terms. |
| **Q4 – Production (Uptime ≥ 99.5 %, radiologist read‑time reduction ≥ 15 %)** | Provides **commercial‑ready evidence** of ROI and regulatory compliance (HIPAA‑audit ready); signals readiness for revenue generation and scale‑out. | **Close Series A** (or Series A extension) by Month 12, using production metrics as the final proof point for scaling to additional networks and pursuing strategic hospital partnerships. |

**Investor‑ready artifacts to prepare at each marker:**  

- **Q2:** Validation report (AUC, confusion matrix, active‑learning efficiency), HIPAA audit log sample, MONAI‑NIM performance benchmarks.  
- **Q3:** FL convergence curves, privacy‑preservation attestation (third‑party), model improvement vs. local baselines, cost‑savings projection from reduced annotation.  
- **Q4:** Production SLA dashboard (uptime, latency), radiologist time‑motion study, deployment reference architecture, letters of intent (LoI) from the three pilot hospitals.

---

### Closing Note  
By aligning the **technical roadmap** with **NVIDIA’s Inception stack (NIM, MONAI, FLARE)**, activating **GPU credits** at the right cadence, and completing **targeted DLI training**, ClaraVision will move from a stalled prototype to a **production‑grade, federated anomaly‑detection platform** that delivers measurable clinical impact and solidifies the data‑flywheel narrative essential for the next fundraising round.